The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions.

Patients diagnosed with type 2 diabetes have an increased risk of developing cardiovascular complications. The researchers are currently working on understanding how to prevent these progressions from occurring. Since 2006, dipeptidyl-peptidase-4 inhibitors have been made available to patients as a relatively new treatment for diabetes. These substances inhibit the enzyme known as dipeptidyl peptidase-4 (DPP-4), which in turn increases the levels of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This results in an increase in the effectiveness of insulin release after meals, which in turn has a positive impact on glycemic control. Regarding the safety of this category of medication in the treatment of cardiovascular disorders, there have been a great deal of debates. Emerging research suggests that DPP-4 inhibitors could be useful in the treatment of a variety of cardiovascular conditions, including coronary atherosclerosis, heart failure, and hypertension, among others. In order to investigate the possibility of using dipeptidyl-peptidase-4 inhibitors as a treatment option for cardiovascular disease, the molecular pathways that are thought to be responsible for their cardioprotective effect will be clarifies throughout the course of this review.